Search results
Results from the Tech24 Deals Content Network
In April 2019, following a large-scale ring-vaccination scheme in the DRC outbreak, the WHO published the preliminary results of its research, in association with the DRC's Institut National pour la Recherche Biomedicale, into the effectiveness of the ring vaccination program, stating that the rVSV-ZEBOV-GP vaccine had been 97.5% effective at stopping Ebola transmission, relative to no ...
rVSV-ZEBOV. VSV-EBOV or rVSV-ZEBOV, sold under the brand name Ervebo, is a vaccine based on the vesicular stomatitis virus which was genetically modified to express a surface glycoprotein of Zaire Ebola virus. [ 16][ 17] In November 2019, the European Commission granted a conditional marketing authorization. [ 18]
ZMapp is an experimental biopharmaceutical drug comprising three chimeric monoclonal antibodies under development as a treatment for Ebola virus disease. [1] Two of the three components were originally developed at the Public Health Agency of Canada's National Microbiology Laboratory (NML), and the third at the U.S. Army Medical Research Institute of Infectious Diseases; the cocktail was ...
A month ago the European Union issued marketing authorization for a vaccine to prevent the Ebola virus in adults, and now the FDA has approved it. While noting that Ebola cases in the US have been ...
The vaccine, developed by the pharmaceutical giant Merck, is known as Ervebo. It's the first human Ebola vaccine to be approved by the EU. Ervebo was first engineered by the Public Health Agency ...
By 20 October, Canada had pledged 65.4 million Canadian dollars to the fight against Ebola. As part of its contribution, Canada has deployed two mobile diagnostic laboratories in Sierra Leone, and shipped the first batch of an experimental Ebola vaccine to the WHO in Geneva. [92]
An Ebola vaccine has proven to be 100 percent effective during test trials in Guinea. The shot has yet to be approved by a regulator, but Gavi, the Vaccine Alliance, has already committed $5 ...
Judie Alimonti. Judie Barbara Alimonti (1960–2017) was a Canadian immunologist known for her research on the RVSV-ZEBOV Ebola vaccine. [1] In 1991, Alimonti received a Bachelor of Science degree in microbiology from the University of British Columbia. She later earned a PhD in immunology from the University of Manitoba. [1]